The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

por Harshman, L C, Fougeray, R, Choueiri, T K, Schutz, F A, Salhi, Y, Rosenberg, J E, Bellmunt, J
Publicado 2013

Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis

por Yoshino, T., Van Cutsem, E., Li, J., Shen, L., Kim, T.W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., Amellal, N., Ohtsu, A., Mayer, R.J.
Publicado 2022

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

por Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Publicado 2021

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

por Bordonaro, R., Calvo, A., Auriemma, A., Hollebecque, A., Rubovszky, G., Saunders, M.P., Pápai, Z., Prager, G., Stein, A., André, T., Argilés, G., Cubillo, A., Dahan, L., Edeline, J., Leger, C., Cattan, V., Fougeray, R., Amellal, N., Tabernero, J.
Publicado 2021

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

por Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., Moiseyenko, V.
Publicado 2022